Response to Neoadjuvant Endocrine Therapy for Breast Cancer May Vary by Race

TUESDAY, Sept. 20, 2022 -- The response to neoadjuvant endocrine therapy (NET) for hormone receptor-positive breast cancer (HR+BC) may vary by race, according to a study presented at the 15th AACR Conference on the Science of Cancer Health...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news